BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has a beta of 2.65. The stock’s Relative Strength Index (RSI) is 66.03, with weekly volatility at 9.41% and ATR at 0.92. The BCRX stock’s 52-week price range has touched low of $3.30 and a $14.24 high. Its shares traded higher over the last trading session, gaining 11.99% on 05/17/21. The shares fell to a low of $11.90 before closing at $14.38. Intraday shares traded counted 7.46 million, which was -35.6% lower than its 30-day average trading volume of 5.50M. BCRX’s previous close was $12.84 while the outstanding shares total 177.34M.
Investors have identified the Biotechnology company BioCryst Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.38 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
BioCryst Pharmaceuticals Inc. (BCRX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 273.77 million total, with 101.2 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.70 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BCRX sounds very interesting.
Is the stock of BCRX attractive?
In related news, Chief Legal Officer, Barnes Alane P sold 102,780 shares of the company’s stock in a transaction that recorded on May 11. The sale was performed at an average price of 12.04, for a total value of 1,237,471. As the sale deal closes, the Director, ABERCROMBIE GEORGE B now sold 7,000 shares of the company’s stock, valued at 88,900. Also, Senior VP – CMO, Sheridan William P sold 41,250 shares of the company’s stock in a deal that was recorded on Feb 22. The shares were price at an average price of 11.57 per share, with a total market value of 477,262. Following this completion of acquisition, the President & CEO, Stonehouse Jon P now holds 134,278 shares of the company’s stock, valued at 1,117,193. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.80%.
9 out of 11 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on BioCryst Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the BCRX stock. The 12-month mean consensus price target for the company’s shares has been set at $14.56.